Patients with acute respiratory distress syndrome and confirmed influenza diagnosis treated ≤6 hours with oseltamivir had reduced length of hospital stay and a lower rate of mortality.
Blacks experience a significantly higher rate of sarcoidosis-associated hospitalizations compared with whites.
No meaningful associations were detected in procedural listing preferences and survival outcomes in patients with COPD or interstitial lung disease awaiting lung transplant.
Health-related quality of life and isolated exertional hypoxia in patients with interstitial lung disease may be improved by the use of ambulatory oxygen.
The primary objective was to characterize the long-term safety and tolerability of Ofev in patients with IPF; efficacy endpoints included annual rate of decline in forced vital capacity (FVC) calculated over 192 weeks.
Nintedanib plus sildenafil did not improve St. George's Respiratory Questionnaire scores in patients with idiopathic pulmonary fibrosis.
Factors predictive of escalated care in infant bronchiolitis include oxygen saturation <90%, nasal flaring/grunting, apnea, retractions, and age 2 months or younger.
Although gastroesophageal reflux disease and idiopathic pulmonary fibrosis may be related, the association between the 2 disorders is most likely confounded by smoking.
The FDA's designation was based on data from a Phase 2 placebo-controlled trial that demonstrated pamrevlumab could potentially address an unmet medical need for this condition.
Laparoscopic antireflux surgery was safe and well tolerated in patients with idiopathic pulmonary fibrosis and abnormal acid gastroesophageal reflux.
Adding routine rheumatologic assessments to interstitial lung disease diagnosis could reduce the need for invasive procedures and improve diagnostic accuracy.
Exposure to ozone, nitrogen dioxide, sulfur dioxide, carbon monoxide, and particulate matter <2.5 μm demonstrated strong associations with acute respiratory distress syndrome.
Rituximab is a safe and effective alternative to cyclophosphamide in managing the progression of scleroderma and subsequent development of interstitial lung disease.
Bronchiolitis obliterans is the leading cause of morbidity and mortality in the pulmonary transplant population with ≥50% of patients who receive a lung transplant developing the condition within 5 years.
Targeting TGF-β signaling in a tissue-specific manner allows the drug to modulate the fibrotic cascade with maximum clinical effects while avoiding adverse events.
An expert panel developed suggestions for chronic cough management in interstitial lung disease, but more clinical trials are needed to establish recommendations.
Pfizer has terminated the ALLOZITHRO trial (N=480) due to this increased risk.
Many patients with idiopathic pulmonary fibrosis in an international phase 4 study tolerated combination therapy with pirfenidone and nintedanib.
Compared with individuals who had stable idiopathic pulmonary fibrosis, those with an acute exacerbation had a significantly shorter survival, especially at the 3 year follow-up.
Low nailfold capillary density is associated with impaired pulmonary function tests and more frequent high-resolution computed tomography abnormalities in patients with juvenile dermatomyositis.